Business Context and Reporting Period
MIRA Pharmaceuticals, Inc. (MIRA), an emerging growth company incorporated in Florida, filed this Form 8-K on August 6, 2026. The report discloses a material event under Item 7.01 (Regulation FD Disclosure) regarding preclinical development progress for its investigational drug candidate, SKNY-1.
Key Financial Metrics
This filing is a current report regarding a specific corporate event and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Developments
- SKNY-1 Toxicokinetic Study: The Company announced positive findings from a 7-day repeated-dose study of SKNY-1 in Beagle dogs.
- Study Results: SKNY-1 demonstrated rapid oral absorption and dose-dependent systemic exposure. Plasma concentrations were comparable between male and female animals.
- Development Impact: The data indicates a dose-dependent response and systemic accumulation, which the Company states de-risks dose selection for the planned GLP toxicology program required for IND-enabling development.
Outlook, Risks, and Management Commentary
Management believes these findings support advancement toward GLP-compliant toxicology studies. However, the Company notes that additional preclinical efficacy and safety studies are required to further characterize SKNY-1. The filing includes a standard cautionary note regarding forward-looking statements, highlighting risks related to preclinical and clinical development, regulatory approvals, financing needs, and reliance on third parties. The Company undertakes no obligation to update these statements except as required by law.
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.1 for detailed study parameters.
- Review the Company's most recent Form 10-K or 10-Q for current cash runway and financing needs, as this 8-K does not contain financial data.
- Monitor upcoming announcements regarding the initiation of GLP-compliant toxicology studies.
- Assess the timeline for potential IND (Investigational New Drug) application submission based on the completion of required safety studies.